Stock comparison
AbbVie
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ABBV
AbbVie
Market cap
$371.72B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.41B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ABBV | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 55C | 69B | HALO |
| Benjamin Graham | 80A | 73B | ABBV |
| Philip Fisher | 53C | 55C | HALO |
| Peter Lynch | 22F | 43D | HALO |
| Joel Greenblatt | 33F | 30F | ABBV |
| Charlie Munger | 60C | 70B | HALO |
| Terry Smith | 57C | 74B | HALO |
Side-by-side metrics
| Metric | ABBV | HALO |
|---|---|---|
| Market cap | $371.72B | $8.41B |
| P/E (TTM) | 102.6x | 24.0x |
| EV/EBIT | 21.7x | 10.2x |
| ROIC (TTM) | 10.29% | 23.65% |
| Gross margin | 73.46% | 81.24% |
| Net margin | 5.79% | 23.13% |
| Revenue CAGR 5y | 2.14% | 33.23% |
| EPS CAGR 5y | -22.23% | -1.98% |
| Debt / Equity | 2.6x | 1.0x |
| Dividend yield | 3.2% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ABBV leads on
- Dividend yield3.2%vs 0.0%+100%
- Market cap$371.72Bvs $8.41B+98%
HALO leads on
- Revenue CAGR 5y33.23%vs 2.14%+94%
- EPS CAGR 5y-1.98%vs -22.23%+91%
- P/E (TTM)24.0xvs 102.6x+77%
- Net margin23.13%vs 5.79%+75%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.